Status:
TERMINATED
Study Evaluating Efficacy and Safety of PF-04523655 Versus Laser in Subjects With Diabetic Macular Edema
Lead Sponsor:
Quark Pharmaceuticals
Collaborating Sponsors:
Pfizer
Conditions:
Diabetic Retinopathy
Diabetes Complications
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To evaluate the effectiveness of study drug in improving visual acuity compared to laser treatment in the patients with diabetic macular edema
Detailed Description
DEGAS termination decision date was December 17, 2010. Rationale: the objectives of the study could no longer be achieved. The study was not terminated for safety.
Eligibility Criteria
Inclusion
- Patients with Diabetes Mellitus (Type 1 or Type 2) Showing Diabetic Macular Edema in the Eye.
Exclusion
- Proliferative Diabetic Retinopathy in the Study Eye.
- Subjects Receiving Concomitant Intravitreal Anti-VEGF Therapy.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT00701181
Start Date
June 1 2008
End Date
January 1 2011
Last Update
October 11 2012
Active Locations (53)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Mesa, Arizona, United States, 85210
2
Pfizer Investigational Site
Meza, Arizona, United States, 85210
3
Pfizer Investigational Site
Peoria, Arizona, United States, 85381
4
Pfizer Investigational Site
Phoenix, Arizona, United States, 85014